What does the Watchman FLX clinical trial compare?

The Watchman FLX clinical trial specifically investigates the efficacy of Left Atrial Appendage Occlusion (LAAO) using the Watchman FLX device compared to oral anticoagulation (OAC) in patients with atrial fibrillation (AF). This comparison is crucial because it addresses the management of stroke risk in AF patients, particularly those who may be at increased risk for bleeding complications associated with long-term anticoagulation therapy. By comparing these two approaches, the trial aims to establish the safety and effectiveness of the Watchman device as a viable alternative to traditional anticoagulation methods for reducing the risk of thromboembolic events.

The other options do not represent the focus of the Watchman FLX trial. While studies on dual vs. single anti-platelet therapies, heart rate-lowering medications versus OAC, and device therapy versus no therapy are important in cardiovascular research, they are not the primary concern of the Watchman FLX clinical trial, which is centered on the comparison between LAAO and OAC specifically in the AF population.